Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain
Joint Authors
Deie, Masataka
Hayashi, Kazuhiro
Ikemoto, Tatsunori
Ueno, Takefumi
Arai, Young-Chang
Wakao, Norimitsu
Hirasawa, Atsuhiko
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-12-28
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
The aim of this study was to confirm the effectiveness of open-label placebo (OLP) in Japanese patients with chronic low back pain (CLBP), similar to previous reports, and to investigate its short- and medium-term effects in this study population.
Methods.
Fifty-two patients with CLBP were randomized into a treatment as usual (TAU) group (n = 26) or an OLP + TAU group (n = 26) for 12 weeks.
The TAU included advice to remain active and exercise in conjunction with recent psychological education based on a self-management strategy.
In contrast, participants in the OLP + TAU group were instructed to take two OLP capsules a day.
Outcome measures were assessed at baseline and at weeks 3 and 12 using the Roland–Morris Disability Questionnaire (RMDQ), Numerical Rating Scale (NRS) for pain intensity, and the Timed-Up-and-Go (TUG) test.
Difference in outcomes between the two groups was compared at the two follow-up points.
Results.
Although all participants completed the 3-week follow-up, four patients (two in each group) were lost to follow-up beyond week 3.
There were no significant intergroup differences in changes in the RMDQ score (p=0.40), pain-NRS score (p=0.19), and TUG time (p=0.98) at week 3.
Two-way repeated measure analyses of covariance showed significant time-course effects but did not show group effects or any interactions between the time-course and group in terms of the RMDQ score.
However, it did not show any effects in the pain-NRS score and TUG time at week 12.
Conclusions.
The OLP + TAU group showed no superior findings in comparison with the TAU group after 3 weeks and 12 weeks for Japanese patients with CLBP.
Nonetheless, significant improvements in functional disability were observed in both groups.
American Psychological Association (APA)
Ikemoto, Tatsunori& Ueno, Takefumi& Arai, Young-Chang& Wakao, Norimitsu& Hirasawa, Atsuhiko& Hayashi, Kazuhiro…[et al.]. 2020. Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain. Pain Research and Management،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1206936
Modern Language Association (MLA)
Ikemoto, Tatsunori…[et al.]. Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain. Pain Research and Management No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1206936
American Medical Association (AMA)
Ikemoto, Tatsunori& Ueno, Takefumi& Arai, Young-Chang& Wakao, Norimitsu& Hirasawa, Atsuhiko& Hayashi, Kazuhiro…[et al.]. Open-Label Placebo Trial among Japanese Patients with Chronic Low Back Pain. Pain Research and Management. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1206936
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206936